The agency first declared a shortage of semaglutide, the main ingredient used to make Ozempic and Wegovy, in 2022. The FDA's announcement comes months after drugmaker Novo Nordisk told the agency ...

Ozempic and Wegovy, the widely popular forms of semaglutide sold to treat diabetes and obesity, have officially been removed from the Food and Drug Administration’s (FDA) drug shortage list ...

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window The shortage of semaglutide injections (Ozempic, Wegovy) is over, the FDA announced on Friday. The agency, along with ...

Wegovy and Ozempic, both known chemically as semaglutide, were in shortage in the U.S. for much of last year. More on semaglutide compounds:Shortage of popular drugs Wegovy and Ozempic is over ...

The semaglutide shortage has officially ended ... At the end of October, the FDA changed the status of all dosages of Ozempic and Wegovy to “available,” signaling that the end of the official ...

Novo’s semaglutide, sold under the brand names Ozempic for diabetes and Wegovy for obesity, had been on the FDA’s drug shortage list for over two years. During that time, patients flocked to ...

Blockbuster weight-loss and diabetes drugs Wegovy and Ozempic are no longer in shortage, the US Food and Drug Administration said on Friday. The update about the popular semaglutide injections ...

The Food and Drug Administration said on Friday that there is no longer a shortage of drugs like Wegovy and Ozempic. The semaglutide known as Ozempic is intended to be used for people with diabetes.